Next-Generation Sequencing Data Analysis Market to Reach USD 5.4 Bn by 2032 | Transparency Market Research

Global next-generation sequencing data analysis market growth is driven by the rise in demand for computational analysis of next-generation sequencing (NSG) data in oncology to identify genomic variations in numerous types of tumors.

Wilmington, Delaware, United States, April 12, 2023 (GLOBE NEWSWIRE) -- The global next-generation sequencing data analysis market was valued at USD 610.6 Mn in 2021 and is projected to reach USD 5.4 Bn by 2032 growing at a CAGR of 16.6%.

Integration of genome medicine into clinical practice is expected to bolster market development. Development of personalized medicine is anticipated to drive the usage of NSG data analysis tools. Surge in usage of NSG to identify mutation patterns and genetic variations in cancer, rare infectious diseases, and autism through whole genome sequencing is likely to augment the market size.

Download a Sample for Highlights on Market Drivers and Challenges Affecting the Next-Generation Sequencing Data Analysis:

Market Snapshot:

Report Coverage Details
Market Revenue USD 610.6 Mn in 2021
Estimated Value USD 5.4 Bn by 2032
Growth Rate 16.6% 
Forecast Period 2022–2032
No. of Pages 250 Pages
Segmentation By Read Length, Product Type, Workflow, Sourcing Type, and Region
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, South America
Companies CoveredThermo Fisher Scientific, Inc., Qiagen, Illumina, Inc., F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., PierianDx, Precigen Bioinformatics Germany GmbH, Partek Incorporated, Eurofins Scientific, Pacific Biosciences of California, Inc., DNASTAR, Inc., Congenica Ltd., Fabric Genomics, Inc., Genuity Science, DNAnexus Inc., SciGenom Labs Pvt. Ltd., Golden Helix, Inc., and Verily Life Science

In terms of workflow, the tertiary segment led the global next-generation sequencing data analysis market in 2021. Rise in usage of tertiary workflow to analyze large volumes of sequencing data related to proteins, signaling pathways, and phenotypes is expected to fuel the segment. Increase in trend of application of novel statistical tools for NGS data analysis is likely to bolster market development. Surge in demand for innovative tertiary data analysis tools to interpret sequencing data is estimated to boost the segment. An example is tertiary data analysis of RNA-Seq data.

Key Findings of Study

  • Significant Adoption of Cloud-based NSG Platforms: Surge in demand for cloud-based NSG bioinformatics platform is expected to propel the market. Cloud computing solutions are projected to be utilized by researchers to analyze NSG data that is freely available. An instance is availability of large volumes of NSG data in The International Cancer Genome Consortium (ICGC). Surge in R&D in identifying genetic variations for a number of common cancer types is expected to bolster utilization of cloud-based NSG bioinformatics platform.
  • Rise in Usage of Next-Generation Sequencing in Oncology to Offer Lucrative Opportunities: Rise in trend of utilizing next generation sequencing data in clinical oncology is anticipated to bolster the market. Growth in usage of NSG data analysis in cancer genomics program by governments of several countries, especially the U.S. and the U.K., is expected to accelerate next-generation sequencing data analysis market development. Instance is the rise in demand bioinformatics tools by researchers for data analysis generated in The Cancer Genome Atlas (TCGA). Another instance is government initiatives in The International Cancer Genome Consortium (ICGC) to promote cancer genetic understanding. Furthermore, NSG data analysis has the potential to enable personalized treatment by targeting genomic changes in individual tumors.


Key Drivers

  • Rise in trend of utilization of the next-generation sequencing (NSG) technology in whole genome sequencing and exome sequencing is expected to drive the demand for NSG data analysis. Decline in cost of the NSG technology and increase in its accuracy are bolstering the adoption of the technology in large-scale genome projects.
  • Surge in demand for effective diagnostics for genetic disorders is propelling the usage of NSG-based diagnostics, particularly for cancer. Thus, extensive R&D in cancer genomics in the past few years has boosted the application of NSG. This has created significant need for advanced NSG data analysis workflow.
  • Rise in usage of NSG in transcriptomics and proteomics is projected to broaden the next-generation sequencing data analysis market outlook

Regional Growth Dynamics

The market in Europe is anticipated to witness significant revenue growth during the forecast period. Rise in government investment in genome sequencing projects in the U.K, Iceland, Sweden, and Finland is expected to drive the usage of tools for analyzing data from next-generation sequencing (NGS), complex genomic analyses. Examples are 1000 Genomes Project and International HapMap, where NSG was used as cost-effective and reliable technology for sequencing of several genomes from patients suffering from cancer and rare diseases. Demand for NSG analysis tools for understanding genetic background of these diseases is likely to propel the market.

The market in the U.K. is projected to reach US$ 348 Mn by 2032, representing a CAGR of 26.7% from 2022 to 2032.

The U.S., China, Japan, and South Korea are projected to offer lucrative opportunities to companies in the next-generation sequencing data analysis market. Surge in utilization of NSG for whole-genome sequencing in these countries, driven by focus on development of precision medicine in cancer, is expected to generate significant revenues for companies in the near future.

The U.S. held leading share of the global market in 2021. The U.S. market is expected to advance at a CAGR of 23.4% from 2022 to 2032.

Competition Landscape

Prominent companies in the market are Thermo Fisher Scientific, Qiagen, Illumina, F. Hoffmann - La Roche Ltd., Agilent Technologies, Genuity Science, Fabric Genomics, Bio-Rad Laboratories, Inc., PierianDX, Partek Incorporated, DNASTAR Inc., Congenica, Eurofins Scientific, Pacific Biosciences of California, Inc., and DNAnexus, Inc.

Browse the Full Report with Facts and Figures of the Next-Generation Sequencing Data Analysis Market:

Next-Generation Sequencing Data Analysis Market Segmentation

By Read Length

  • Long Read Sequencing
  • Short Read Sequencing
  • Very Long Read Sequencing

By Product Type

  • Services
  • NSG Commercial Software

By Workflow

  • Secondary
  • Tertiary
  • Primary

By Sourcing Type

  • Outsourced
  • In-house

By Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Nikhil Sawlani
Transparency Market Research Inc.
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453